# Relapsing Multiple Sclerosis FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/relapsing-multiple-sclerosis

> 9 upcoming FDA catalysts in relapsing Multiple Sclerosis: imu-838 tablets (IMUX) on Dec 2026 (topline data readout); BRIUMVI® (ublituximab, TGTX) on Jan to Apr 2027 (topline data readout); BRIUMVI® (ublituximab, TGTX) on January 2027 (primary completion); Kesimpta (ofatumumab, NVS) on Sep to Dec 2028 (topline data readout); and 5 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| August 28, 2025 | [Obexelimab primary completion](https://sec-api.dev/pdufa/obexelimab) | ZBIO | Relapsing Multiple Sclerosis | completed | "NCT06564311 (A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2025-08-28 (ACTUAL); Lead Sponsor Zenas BioPharma (USA), LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06564311)) |
| July 21, 2026 | [Rhapsido® (remibrutinib) primary completion](https://sec-api.dev/pdufa/remibrutinib) | NVS | Relapsing Multiple Sclerosis | completed | "NCT05147220 (Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-07-21 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05147220)) |
| July 22, 2026 | [Rhapsido® (remibrutinib) primary completion](https://sec-api.dev/pdufa/remibrutinib) | NVS | Relapsing Multiple Sclerosis | completed | "NCT05156281 (Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-07-22 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05156281)) |
| Oct 2026 to Jan 2027 | [BRIUMVI® (ublituximab) topline data readout](https://sec-api.dev/pdufa/ublituximab) | TGTX | Relapsing Multiple Sclerosis | scheduled | "NCT07211633 (A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-31 (ESTIMATED); Lead Sponsor TG Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07211633)) |
| October 2026 | [BRIUMVI® (ublituximab) primary completion](https://sec-api.dev/pdufa/ublituximab) | TGTX | Relapsing Multiple Sclerosis | delayed | "NCT07211633 (A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-31 (ESTIMATED); Lead Sponsor TG Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07211633)) |
| Dec 2026 | [Imu-838 tablets topline data readout](https://sec-api.dev/pdufa/imu-838) | IMUX | relapsing multiple sclerosis | scheduled | "The company's lead investigational asset, vidofludimus calcium (IMU-838), is currently being evaluated in Phase 3 clinical trials in relapsing multiple sclerosis, with top-line data expected to be available in December 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1280776/000149315226051543/ex99-1.htm)) |
| Jan to Apr 2027 | [BRIUMVI® (ublituximab) topline data readout](https://sec-api.dev/pdufa/ublituximab) | TGTX | Relapsing Multiple Sclerosis | scheduled | "NCT05877963 (Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-01-21 (ESTIMATED); Lead Sponsor TG Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05877963)) |
| January 2027 | [BRIUMVI® (ublituximab) primary completion](https://sec-api.dev/pdufa/ublituximab) | TGTX | Relapsing Multiple Sclerosis | scheduled | "NCT05877963 (Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-01-21 (ESTIMATED); Lead Sponsor TG Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05877963)) |
| Sep to Dec 2028 | [Kesimpta (ofatumumab) topline data readout](https://sec-api.dev/pdufa/ofatumumab) | NVS | Relapsing Multiple Sclerosis | scheduled | "NCT03650114 (Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-09-30 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03650114)) |
| September 2028 | [Kesimpta (ofatumumab) primary completion](https://sec-api.dev/pdufa/ofatumumab) | NVS | Relapsing Multiple Sclerosis | scheduled | "NCT03650114 (Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-09-30 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03650114)) |
| Jul to Oct 2029 | [Remibrutinib oral treatment topline data readout](https://sec-api.dev/pdufa/remibrutinib-oral-treatment) | NVS | Relapsing Multiple Sclerosis | scheduled | "NCT06846281 (Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-07-25 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06846281)) |
| July 2029 | [Remibrutinib oral treatment primary completion](https://sec-api.dev/pdufa/remibrutinib-oral-treatment) | NVS | Relapsing Multiple Sclerosis | scheduled | "NCT06846281 (Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-07-25 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06846281)) |
| January 2030 | [BRIUMVI® (ublituximab) primary completion](https://sec-api.dev/pdufa/ublituximab) | TGTX | Relapsing Multiple Sclerosis | scheduled | "NCT07220252 (Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2030-01-01 (ESTIMATED); Lead Sponsor TG Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07220252)) |
| Jan to Apr 2030 | [BRIUMVI® (ublituximab) topline data readout](https://sec-api.dev/pdufa/ublituximab) | TGTX | Relapsing Multiple Sclerosis | scheduled | "NCT07220252 (Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2030-01-01 (ESTIMATED); Lead Sponsor TG Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07220252)) |

## Drugs

- [Obexelimab](https://sec-api.dev/pdufa/obexelimab) (ZBIO)
- [Rhapsido® (remibrutinib)](https://sec-api.dev/pdufa/remibrutinib) (NVS)
- [BRIUMVI® (ublituximab)](https://sec-api.dev/pdufa/ublituximab) (TGTX)
- [Imu-838 tablets](https://sec-api.dev/pdufa/imu-838) (IMUX)
- [Kesimpta (ofatumumab)](https://sec-api.dev/pdufa/ofatumumab) (NVS)
- [Remibrutinib oral treatment](https://sec-api.dev/pdufa/remibrutinib-oral-treatment) (NVS)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/relapsing-multiple-sclerosis.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Relapsing Multiple Sclerosis FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/relapsing-multiple-sclerosis

```bibtex
@misc{secapidev_indications_relapsing_multiple_sclerosis_20261116,
  title        = {Relapsing Multiple Sclerosis FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/relapsing-multiple-sclerosis}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_relapsing_multiple_sclerosis_20261116","title":"Relapsing Multiple Sclerosis FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/relapsing-multiple-sclerosis","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
